Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in primary sclerosing cholangitis
ISRCTN15271834Phase 2Completed
- Sponsor
- Norfolk and Norwich University Hospitals NHS Foundation Trust
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of brodalumab in Primary Sclerosing Cholangitis (PSC), sponsored by Norfolk and Norwich University Hospitals NHS Foundation Trust. Primary endpoints: Recruitment and retention feasibility, Medication adherence and 5 more. Started Feb 2024; status: completed.
02
Drugs
brodalumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on ISRCTN15271834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15271834.